Weekly Report on China's Big Health Industry: Top 5 Domestic Pharma CXOs Employ Over 3,000 PhD Researchers; Kangzhong Medical Acquires 30% Stake in UK-Based ISDI

China's Top 5 Pharma CXOs Have Over 3,000 PhDs in R&D Staff

China's Top Five Pharmaceutical CXO Companies: WuXi AppTec, WuXi Biologics, Tigermed, ChemPartner, and Asymchem, Employ Over 3,000 PhD Holders Among Their Large R&D Teams. These companies primarily focus on pharmaceutical R&D services, covering areas such as CRO and CDMO, providing new drug R&D and manufacturing services to global pharmaceutical, life science, and medical device companies, accelerating drug innovation and reducing R&D costs. In 2023, these enterprises demonstrated strong revenue and net profit performance, supported by their extensive R&D workforce. (Source: Arterial Network)

CareRay Digital Medical Technology Co., Ltd. Completes Acquisition of 30% Stake in UK-based ISDI

On April 18, 2024, CareRay Digital Medical Technology Co., Ltd. completed the acquisition of 30% equity in ISDI LIMITED, a UK-based high-end X-ray flat panel detector and CMOS sensor R&D and manufacturing company. Regarding this strategic business expansion, Liu Jianqiang, Chairman of CareRay, stated: "We are very pleased to have reached this milestone cross-border cooperation with ISDI. ISDI's CMOS flat panel detectors and sensor products have technological advantages globally, and their team has extensive industry experience with years of dedication to the semiconductor and X-ray imaging fields. We look forward to this collaboration enabling both parties to fully leverage their respective strengths, engage in deep exchange and cooperation, and jointly provide high-performance, high-quality innovative solutions to global partners." (Source: cnstock.com)

Dian Diagnostics Group's Vietnam Subsidiary Opens

Dian Diagnostics Opens First Overseas Medical Laboratory and Product Channel Business in Vietnam, Marking a New Phase of "Service + Product" in Its International Operations

Hengrui Pharma's Two New Cancer Drugs Proposed for Priority Review

Hengrui Pharma's Two New Cancer Drugs, Fuzoparib Capsules and Apatinib, Proposed for Priority Review to Treat HER2-Negative Breast Cancer with Germline BRCA Mutations

IMPACT Therapeutics Announces Successful Completion of RMB 400 Million D+ Round Financing

IMPACT Therapeutics, an innovative drug research and development company focusing on the mechanism of synthetic lethality in tumors, announced the successful completion of its D+ round of financing worth 400 million RMB. This round of financing was jointly led by Gao Tejia Investment and Xicheng Jinrui, with participation from Yangzhou Guojin Group and Guyunan Ge. Existing shareholders, Lilly Asia Ventures and Xiamen C&D Emerging Investment, continued to increase their investment in this round. Zhou Du Capital served as the financial advisor for this round of financing. (Source: Arterial Network)

Neuromodulation Platform Company - SNEURO MEDICAL Completes Hundreds of Millions of B+ Round Financing

Recently, SNEURO MEDICAL (Hangzhou Shenluo Medical Technology Co., Ltd.) announced that it has secured hundreds of millions in its Series B+ funding round. The round was led by OrbiMed with participation from existing investor Boyuan Capital. The proceeds will primarily be used for SNEURO MEDICAL’s new product development, clinical research, registration applications, core technology iteration, and commercial expansion. (Source: Arterial Network)

Yi尊 Bio Completes Nearly RMB100 Million A+ Round Financing

Recently, Yizun Biomedical (Zhejiang) Co., Ltd. ("Yizun Bio") completed a nearly RMB 100 million Series A+ round of financing. This round was jointly led by Tylon Investment and Taiyu Investment, with participation from Mr. Zheng Xiaodong, Chairman of Dongfu Dragon, and Hangzhou Binjiang 5050 Fund. Lightsource Capital served as the exclusive financial advisor. The proceeds will be used to advance Yizun Bio's clinical research, regulatory submissions, and team building. (Source: Arterial Network)

Cellatopia Successfully Raises Nearly RMB 10 Million in Seed Funding

Recently, a young biotech star in Suzhou Industrial Park — Suzhou Xitong Biotechnology Co., Ltd. (hereinafter referred to as "Xitong Bio") announced the successful completion of a seed round of financing worth nearly RMB 10 million. This round of financing was led by Suzhou Shishangbai Venture Partnership, with participation from institutions such as Suzhou Nuowei Venture Investment Co., Ltd. They highly praised Xitong Bio's product design philosophy, innovative R&D capabilities, market prospects, and team competence, expressing their willingness for long-term cooperation. (Source: Arterial Network)

Dian Diagnostics Group Discloses 2023 Annual Report: Revenue of 13.4 Billion Yuan, Workforce Reduced by 2,285

Dian Diagnostics Group Reports 2023 Revenue of 13.4 Billion Yuan, Down 33.89% Year-on-Year, with Net Profit Plunging 78.56%. Workforce Reduced by 2,285 Employees, Executive Compensation Cut. Company Focuses on Six Key Initiatives to Drive Strategic Implementation; Diagnostic Services Revenue Grows by 11.91%. Optimizes Organizational Management Model, Accelerates Digital Intelligence Strategy, While Ensuring Health Services for the Hangzhou Asian Games. (Source: Arterial Network)

New Policy for Beijing's Digital Medical Industry; China's Medical Software Market to Reach 35.75 Billion

Beijing Launches New Digital Healthcare Industry Policy, Encouraging Large-Scale Model Training in Pharmaceuticals and Health, and the Trading and Circulation of Medical and Health Data. Meanwhile, China’s Medical Imaging Equipment Market is Growing Rapidly, but the EU Plans to Investigate the Procurement of Chinese Medical Devices, Impacting Related Companies’ Stock Prices. Additionally, the Medical Software Market Size Will Continue to Expand, with Tencent's Medical Imaging AI Platform Passing Comprehensive Performance Evaluation. Chaoyang District Also Announced a Digital Healthcare Industry Innovation Development Plan and Support Policies. (Source: Arterial Network)